Insulin Resistance > Liraglutide

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

Recruiting in Palo Alto (17 mi)

Overseen By Peter D Reaven, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Phoenix VA Health Care System

Prior Safety Data

Approved in 4 jurisdictions

Trial Summary

What is the purpose of this trial?

In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.

Eligibility Criteria

Participant Groups

Group I: Liraglutide Experimental Treatment 1 Intervention

Liraglutide titration up to 1.8 mg/d over approximately 3 weeks

Group II: Sugar pill Placebo Group 1 Intervention

matching placebo and titration

Liraglutide is already approved in United States, United States, European Union, European Union for the following indications:

🇺🇸 Approved in United States as Victoza for:

• Type 2 diabetes mellitus treatment
• Cardiovascular risk reduction in adults with type 2 diabetes and heart disease

🇺🇸 Approved in United States as Saxenda for:

• Weight loss treatment in adults and children aged 12 and older with obesity

🇪🇺 Approved in European Union as Victoza for:

• Type 2 diabetes mellitus treatment
• Cardiovascular risk reduction in adults with type 2 diabetes and heart disease

🇪🇺 Approved in European Union as Saxenda for:

• Weight loss treatment in adults and children aged 12 and older with obesity

Find A Clinic Near You

Research locations nearby Select from list below to view details:

Carl T. Hayden VA Medical Hospital Phoenix, AZ

Who is running the clinical trial?

Phoenix VA Health Care System Lead Sponsor

Novo Nordisk A/S Industry Sponsor

References